Ulrich S.
- Country
- Germany
- Department
- Sektion Haemostaseologie
Research Overview
- A phase 3b open-label, multicenter study evaluating physical activity and joint health in previously treated patients ≥12 years of age with severe haemophilia A treated with intravenous recombinant coagulation factor VIII Fc-von Willebrand Factor-XTEN fusion protein (rFVIIIFc-VWF-XTEN; efanesoctocog alfa) for 24 months
- Phase 3 Multicenter Randomized Open‑Label Trial of Efanesoctocog Alfa Intensified Replacement Therapy for Synovitis in Patients with Congenital Hemophilia A
- Evaluation of Nipocalimab for Reducing Severe Fetal and Neonatal Alloimmune Thrombocytopenia Risk in At-risk Pregnancies: A Double-blind, Randomized, Placebo-controlled Trial
Data & Insights
Has run more than one trial at 26 of 82 partner sites.
Specializations
Hemophilia Research
This investigator specializes in treating hemophilia disorders, with particular emphasis on both hemophilia A and B. Their research encompasses innovative therapeutic approaches for patients with varying severity levels.
- Management of FVIII inhibitors
- Physical activity assessment in severe hemophilia
- Gene therapy applications
The investigator's work includes evaluating weekly prophylactic treatments and examining different therapeutic approaches for patients with inhibitors.
Maternal-Fetal Medicine
The investigator focuses on treating serious pregnancy-related conditions, particularly alloimmune disorders affecting fetuses and newborns.
- Hemolytic Disease of Fetus and Newborn (HDFN)
- Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT)
- Preventive interventions in high-risk pregnancies
Their research explores novel therapeutic interventions for managing pregnancy-associated alloimmune conditions.
Innovative Therapeutics
The investigator explores advanced therapeutic modalities across blood disorders and pregnancy-related conditions.
- Novel monoclonal antibody treatments
- Long-acting factor replacements
- Comparative treatment efficacy studies
Their work involves evaluating emerging treatments including nipocalimab and efanesoctocog alfa for various hematological conditions.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.